Arch Biopartners Inc. (TSX Venture: ARCH and OTCQB: ACHFF) announced it has arranged a non-brokered private placement offering of 1,000,000 common shares at $0.60 CAD per share for gross proceeds of $600,000 CAD.

The offering is expected to close on April 2, 2026, subject to regulatory approvals including conditional and final approval from the TSX Venture Exchange and satisfaction of customary closing conditions. All shares issued will be subject to a four-month-and-one-day hold period from the closing date.

The company will use the proceeds as general working capital and for operating expenses not covered by human trial funding grants. No finders' fees will be paid in connection with the offering.

Arch Biopartners develops treatments for acute kidney injury and chronic kidney disease. The company's pipeline includes LSALT peptide in a Phase II trial targeting cardiac surgery-associated acute kidney injury and Cilastatin, a repurposed drug in a Phase II trial targeting toxin-induced acute kidney injury. Both programs are enrolling patients at Canadian clinical sites.

The company currently has 66,933,289 common shares outstanding. The information is based on a company press release.